Zejing Pharmaceutical (688266.SH) has resubmitted its application for H-share issuance and listing to the Hong Kong Stock Exchange and has published the application materials.

date
16:26 13/08/2026
avatar
GMT Eight
Zejing Pharmaceutical (688266.SH) announced that on August 12, 2026, the company re-submitted its application to the Hong Kong Stock Exchange Limited (hereinafter referred to as the "Hong Kong Stock Exchange") for the issuance of H shares and the listing of such shares on the main board of the Hong Kong Stock Exchange. On the same day, the application materials for this issuance and listing were published on the Hong Kong Stock Exchange's website. These application materials were prepared and issued by the company in accordance with the requirements of the Hong Kong Securities and Futures Commission (hereinafter referred to as the "Hong Kong SFC") and the Hong Kong Stock Exchange. They are in draft form and the information contained may be updated and revised in due course. Investors should not make any investment decisions based on the information provided therein.
Zejing Pharmaceutical (688266.SH) announced that on August 12, 2026, the company submitted an application to the Hong Kong Stock Exchange Limited (hereinafter referred to as the "Hong Kong Stock Exchange") for the issuance of H shares and for listing on the main board of the Hong Kong Stock Exchange. On the same day, the application materials for this issuance and listing were published on the Hong Kong Stock Exchange's website. These application materials were prepared and published by the company in accordance with the requirements of the Securities and Futures Commission of Hong Kong (hereinafter referred to as the "SFC") and the Hong Kong Stock Exchange, and they are in draft form. The information contained therein may be updated and revised in a timely manner, and investors should not make any investment decisions based on this information.